An observational study in Hepatitis C, Chronic, sponsored by Hoffmann-La Roche. Completed at 106 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-08-08.
Sponsored by Hoffmann-La Roche · Observational
This observational study will assess predictors of early on-treatment and sustained virological response in treatment-naïve patients with chronic hepatitis C initiated on treatment with Pegasys (peginterferon alfa-2a) or peginterferon alfa-2b and ribavirin. Data will be collected during the treatment period (24 or 48 weeks) and 12 and 24 weeks after the end of treatment. Target sample size is \<2000.
2,709 studies on the registry are indexed under Hepatitis A; 142 are open to participants now.
This study's enrollment of 1,656 is above the median of 250 across 687 observational studies indexed under Hepatitis A.
Browse Hepatitis A studies →Hoffmann-La Roche is the lead sponsor of 2,061 studies on the registry; 85 are open to participants now.
Of its 319 completed or terminated interventional studies of FDA-regulated products, 239 (75%) have results posted.
Counted across the registry records on this site, refreshed daily.
Patients receiving peginterferon alfa treatment at a medical centre
Exclusion Criteria:
Participants chronically infected with the hepatitis C virus including genotypes 1 to 6.
Drug: Peginterferon alfa-2a [Pegasys] · Drug: Peginterferon alfa-2b [PegIntron®]
Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
Peginterferon/ribavirin treatment period as prescribed by treating physician (e.g. 24 or 48 weeks) and treatment-free follow-up period of 24 weeks.
Percentage of Participants With Sustained Virological Response by Type of Peginterferon and Genotype in Modified All Treated Population
Sustained virological response (SVR) was defined as virological response (VR) at 24 weeks after end of treatment (EOT). Virological response was defined as hepatitis C virus ribonucleic acid (HCV RNA) of \<15 international units per milliliter (IU/mL) as assessed by COBAS AmpliPrep/COBAS TaqMan (CAP/CTM) or another HCV RNA test with at least the same degree of sensitivity. The CAP/CTM test is an in vitro nucleic acid amplification test for the quantification of HCV. This test possesses a high sensitivity (lower limit of detection \[LLOD\] 15 IU/mL) and a broad linear range of quantification (43 IU/mL up to 69 million IU/mL) in all HCV genotypes. The SVR is reported in treatment naive HCV mono-infected modified all-treated (mTRT) population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b. The EOT was 12, 24, 48 or 72 weeks after initiation of treatment.
Time frame: At 24 weeks (Wk) after EOT
Percentage of Participants With Sustained Virological Response by Type of Peginterferon and Genotype in Per Protocol Population
Sustained virological response was defined as VR at 24 weeks after EOT. Virological response was defined as HCV RNA of \<15 IU/mL as assessed by CAP/CTM or another HCV RNA test with at least the same degree of sensitivity. The CAP/CTM test is an in vitro nucleic acid amplification test for the quantification of HCV. This test possesses a high sensitivity (LLOD 15 IU/mL) and a broad linear range of quantification (43 IU/mL up to 69 million IU/mL) in all HCV genotypes. The SVR is reported in treatment naive HCV mono-infected per protocol (PP) population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b. The EOT was 12, 24, 48 or 72 weeks after initiation of treatment.
Time frame: At 24 weeks after EOT
Percentage of Participants With Modified Sustained Virological Response Over Time by Type of Peginterferon and Genotype in Modified All Treated Population
Modified sustained virological response (mSVR) was defined as modified virological response (mVR) of HCV RNA \<50 IU/mL at 24 weeks after EOT. The mSVR is reported in treatment naive HCV mono-infected mTRT population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b. The EOT was 12, 24, 48 or 72 weeks after initiation of treatment.
Time frame: At 24 weeks after EOT
Percentage of Participants With Modified Sustained Virological Response by Type of Peginterferon and Genotype in Per Protocol Population
Modified sustained virological response is defined as mVR of HCV RNA \<50 IU/mL at 24 weeks after EOT. The mSVR is reported in treatment naive HCV mono-infected PP population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b. The EOT was 12, 24, 48 or 72 weeks after initiation of treatment.
Time frame: At 24 weeks after EOT
Percentage of Participants With Predictive Values of Virological Response by Week 4 and 12 on Modified Sustained Virological Response After Treatment Initiation in Modified All Treated Population
The probability that a participant who developed VR by Week 4 and 12 and also achieved mSVR at 24 weeks after EOT was called the positive predictive value (PPV) of the VR by Wk 4 for mSVR. The probability that a participant who failed to develop VR by Wk 4 and 12 and also failed to achieve mSVR at 24 weeks after EOT was called the negative predictive value (NPV) of the VR by Wk 4 and 12 for mSVR. Predictive values of VR are reported in treatment naive HCV mono-infected mTRT participants who received PEG-IFN alfa-2a and PEG-IFN alfa-2b. The EOT was 12, 24, 48 or 72 weeks after initiation of treatment.
Time frame: At 24 weeks after EOT
Percentage of Participants With Predictive Values of Virological Response by Week 4 and 12 on Modified Sustained Virological Response After Treatment Initiation in Per Protocol Population
The probability that a participant who developed VR by Week 4 and 12 and also achieved mSVR at 24 weeks after EOT was called the PPV of the VR by Wk 4 for mSVR. The probability that a participant who failed to develop VR by Wk 4 and 12 and also failed to achieve mSVR at 24 weeks after EOT was called the NPV of the VR by Wk 4 and 12 for mSVR. Predictive values of VR are reported in treatment naive HCV mono-infected PP population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b. The EOT was 12, 24, 48 or 72 weeks after initiation of treatment.
Time frame: At 24 weeks after EOT
Percentage of Participants With Virological Response by Type of Peginterferon and Genotype in Modified All Treated Population Over Time
Virological Response (VR) was defined as HCV RNA \<15 IU/mL as assessed by COBAS AmpliPrep/COBAS TaqMan (HCV) (CAP/CTM) or another HCV RNA test with at least the same degree of sensitivity. The CAP/CTM test is an in vitro nucleic acid amplification test for the quantification of HCV. This test possesses a high sensitivity (lower limit of detection 15 IU/mL) and a broad linear range of quantification (43 IU/mL up to 69 million IU/mL) in all HCV genotypes. PEOT= Post End of Treatment. EOT= 12, 24, 48 or 72 weeks after initiation of treatment.
Time frame: At Week 2, Week 4, Week 12, EOT, and at 12 Weeks after EOT
Percentage of Participants With Virological Response by Type of Peginterferon and Genotype in Per Protocol Population Over Time
Virological response (VR) was defined as HCV RNA \<15 IU/mL as assessed by CAP/CTM or another HCV RNA test with at least the same degree of sensitivity. The CAP/CTM test is an in vitro nucleic acid amplification test for the quantification of HCV. This test possesses a high sensitivity (LLOD 15 IU/mL) and a broad linear range of quantification (43 IU/mL up to 69 million IU/mL) in all HCV genotypes. The VR is reported in treatment naive HCV mono-infected PP population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b. The EOT was 12, 24, 48 or 72 weeks after initiation of treatment. PEOT= Post End of Treatment
Time frame: At Week 2, Week 4, Week 12, EOT, and at 12 Weeks after EOT
Percentage of Participants With Modified Virological Response by Type of Peginterferon and Genotype in Modified All Treated Population Over Time
Modified virological response (mVR) was defined as HCV RNA \<50 IU/mL as assessed by CAP/CTM or another HCV RNA test with at least the same degree of sensitivity. The CAP/CTM test is an in vitro nucleic acid amplification test for the quantification of HCV. This test possesses a high sensitivity (LLOD 15 IU/mL) and a broad linear range of quantification (43 IU/mL up to 69 million IU/mL) in all HCV genotypes. The mVR is reported in treatment naive HCV mono-infected mTRT population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b. The EOT was 12, 24, 48 or 72 weeks after initiation of treatment. PEOT= Post End of Treatment
Time frame: At Week 2, Week 4, Week 12, EOT, and at 12 Weeks after EOT
Percentage of Participants With Modified Virological Response by Type of Peginterferon and Genotype in Per Protocol Population Over Time
Modified virological response (mVR) is defined as HCV RNA \<50 IU/mL as assessed by CAP/CTM or another HCV RNA test with at least the same degree of sensitivity. The CAP/CTM test is an in vitro nucleic acid amplification test for the quantification of HCV. This test possesses a high sensitivity (LLOD 15 IU/mL) and a broad linear range of quantification (43 IU/mL up to 69 million IU/mL) in all HCV genotypes. The mVR is reported in treatment naive HCV mono-infected PP population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b. The EOT was 12, 24, 48 or 72 weeks after initiation of treatment. PEOT= Post End of Treatment
Time frame: At Week 2, Week 4, Week 12, EOT, and at 12 Weeks after EOT
Percentage of Participants With at Least a 2-log10 Drop in Hepatitis C Virus Ribonucleic Acid in Modified All Treated Population at Week 2, Week 4 and Week 12
Participants with 2-logarithm (log) drop in HCV RNA including HCV RNA values \<50 IU/mL in the serum from baseline to Week 2, Week 4 and Week 12, expressed in terms of a logarithmic scale with base 10 were evaluated and reported. A 2 log drop in HCV RNA was defined as drop of HCV viral load by 99%. The 2 log drop in HCV RNA is reported in treatment naive HCV mono-infected mTRT population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b.
Time frame: At Week 2, Week 4 and Week 12
Percentage of Participants With at Least a 2-log10 Drop in Hepatitis C Virus Ribonucleic Acid in Per Protocol Population at Week 2, Week 4 and Week 12
Participants with 2-log drop in HCV RNA including HCV RNA values \<50 IU/mL in the serum from baseline to Week 2, Week 4 and Week 12, expressed in terms of a logarithmic scale with base 10 were evaluated and reported. A 2 log drop in HCV RNA was defined as drop of HCV viral load by 99%. The 2 log drop in HCV RNA is reported in treatment naive HCV mono-infected PP population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b.
Time frame: At Week 2, Week 4 and Week 12
Percentage of Participants With at Least a 1-log10 Drop in Hepatitis C Virus Ribonucleic Acid in Modified All Treated Population at Week 2, Week 4 and Week 12
Participants with 1-log drop in HCV RNA including HCV RNA values \<50 IU/mL in the serum from baseline to Week 2, Week 4 and Week 12, expressed in terms of a logarithmic scale with base 10 were evaluated and reported. A 1- log drop in HCV RNA was defined as drop of HCV viral load by 90%. The 1- log drop in HCV RNA was reported in treatment naive HCV mono-infected mTRT population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b.
Time frame: At Week 2, Week 4 and Week 12
Percentage of Participants With at Least a 1-log10 Drop in Hepatitis C Virus Ribonucleic Acid in Per-Protocol Population at Week 2, Week 4 and Week 12
Participants with 1-log drop in HCV RNA including HCV RNA values \<50 IU/mL in the serum from baseline to Week 2, Week 4 and Week 12, expressed in terms of a logarithmic scale with base 10 were evaluated and reported. A 1- log drop in HCV RNA was defined as drop of HCV viral load by 90%. The 1- log drop in HCV RNA was reported in treatment naive HCV mono-infected PP population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b.
Time frame: At Week 2, Week 4 and Week 12
Percentage of Participants With Predictive Values of Virological Response on Modified Sustained Virological Response After Treatment Initiation in Modified All Treated Population
The probability that a participant who developed VR by Wk 2 achieved mSVR at 24 weeks after EOT was called the PPV of the VR by Wk 4 for mSVR. The probability that a participant who failed to develop VR by Wk 4 and 12 and also failed to achieve mSVR at 24 weeks after EOT was called the NPV of the VR by Wk 4 and 12 for mSVR. Predictive Values of VR was reported in treatment naive HCV mono-infected mTRT population participants who received PEG-IFN alfa-2a and PEG-IFN alfa-2b. The EOT was 12, 24, 48 or 72 weeks after initiation of treatment.
Time frame: At 24 weeks after EOT
Percentage of Participants With Predictive Values of Virological Response on Modified Sustained Virological Response After Treatment Initiation in Per Protocol Population
The probability that a participant who developed VR by Wk 2 and achieved mSVR at 24 weeks after EOT was called the PPV of the VR by Wk 4 for mSVR. The probability that a participant who failed to develop VR by Wk 2 and also failed to achieve mSVR at 24 weeks after EOT was called the NPV of the VR by Wk 2 for mSVR. Predictive values of VR is reported in treatment naive HCV mono-infected PP population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b. The EOT was 12, 24, 48 or 72 weeks after initiation of treatment.
Time frame: At 24 weeks after EOT
Number of Participants With Response by Disjoint Categories in Modified All-Treated Population at Week 4 and Week 12
Rapid virological response (RVR) was defined as VR by Wk 4, Modified rapid virological response (mRVR) was defined as mVR by Wk 4, complete early virological response (cEVR) was defined as VR by Wk 12, but no RVR, modified complete early virological response (mcEVR) was defined as mVR by Wk 12, but no mRVR, partial early virological response (pEVR) was defined as at least a 2-log10 drop in HCV RNA as compared to baseline (including HCV RNA values \<50 IU/mL) by Wk 12, but no RVR and no cEVR, modified partial early virological response (mpEVR) was defined as at least a 2-log10 drop in HCV RNA as compared to baseline by Wk 12, but no mRVR and no mcEVR. The data is reported in treatment naive HCV mono-infected mTRT participants who received PEG-IFN alfa-2a and PEG-IFN alfa-2b.
Time frame: At Week 4 and Week 12
Number of Participants With Response by Disjoint Categories in Per-Protocol Population at Week 4 and Week 12
RVR was defined as as VR by Wk 4, mRVR was defined as mVR by Wk 4, cEVR was defined as VR by Wk 12, but no RVR, mcEVR was defined as mVR by Wk 12, but no mRVR, pEVR was defined as at least a 2-log10 drop in HCV RNA as compared to baseline (including HCV RNA values \<50 IU/mL) by Wk 12, but no RVR and no cEVR, mpEVR was defined as at least a 2-log10 drop in HCV RNA as compared to baseline by Wk 12, but no mRVR and no mcEVR. The data is reported in treatment naive HCV mono-infected PP population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b.
Time frame: During first 12 weeks of treatment
Percentage of Participants With Relapse After Modified End of Treatment Response by Genotype in Modified All-Treated Population at 12 Weeks After End of Treatment
Participants whose last test result in their respective follow-up time window showed mVR were considered to have maintained their modified end of treatment response (mEOT-R). Participants whose last test result in the respective follow-up time window did not show mVR, or who did not have a test result in the respective follow-up time window but whose last follow-up test result before the time window did not show mVR, were considered to have relapsed. Only participants with mEOT-R who had a HCV RNA measurement in the follow-up time window (without use of backward imputation), or whose last HCV RNA measurement at a follow-up time point before the time window did not show mVR, were included in the calculations. The number of participants with relapse was reported in treatment naive mTRT population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b. The EOT was 12, 24, 48 or 72 weeks after initiation of treatment.
Time frame: At 12 weeks after EOT
Percentage of Participants With Relapse After Modified End of Treatment Response by Genotype in Modified All-Treated Population at 24 Weeks After End of Treatment
Participants whose last test result in the follow-up time window showed mVR were considered to have maintained their modified end of treatment response (mEOT-R). Participants whose last test result in the respective follow-up time window did not show mVR, or who did not have a test result in the respective follow-up time window but whose last follow-up test result before the time window did not show mVR, were considered to have relapsed. Only participants with mEOT-R who had a HCV RNA measurement in the follow-up time window (without use of backward imputation), or whose last HCV RNA measurement at a follow-up time point before the time window did not show mVR, were included in the calculations. It was reported in treatment naive HCV mono-infected mTRT population receiving PEG-IFN alfa-2a and PEG-IFN alfa-2b. EOT= 12, 24, 48 or 72 weeks after initiation of treatment. No participants were analysed for arm 'Genotype Unknown'.
Time frame: 24 weeks after EOT
Percentage of Participants With Relapse After Modified End of Treatment Response by Genotype in Per-Protocol Population at 12 Weeks After End of Treatment
Participants whose last test result in the follow-up time window showed mVR were considered to have maintained their modified end of treatment response (mEOT-R). Participants whose last test result in the respective follow-up time window did not show mVR, or who did not have a test result in the respective follow-up time window but whose last follow-up test result before the time window did not show mVR, were considered to have relapsed. Only participants with mEOT-R who had a HCV RNA measurement in the follow-up time window (without use of backward imputation), or whose last HCV RNA measurement at a follow-up time point before the time window did not show mVR, were included in the calculations. It was reported in treatment naive HCV mono-infected PP population receiving PEG-IFN alfa-2a and PEG-IFN alfa-2b. EOT= 12, 24, 48 or 72 weeks after initiation of treatment.
Time frame: At 12 weeks after EOT
Percentage of Participants With Relapse After Modified End of Treatment Response by Genotype in Per-Protocol Population at 24 Weeks After End of Treatment
Participants whose last test result in the follow-up time window showed mVR were considered to have maintained their modified end of treatment response (mEOT-R). Participants whose last test result in the respective follow-up time window did not show mVR, or who did not have a test result in the respective follow-up time window but whose last follow-up test result before the time window did not show mVR, were considered to have relapsed. Only participants with mEOT-R who had a HCV RNA measurement in the follow-up time window (without use of backward imputation), or whose last HCV RNA measurement at a follow-up time point before the time window did not show mVR, were included in the calculations. It was reported in treatment naive HCV mono-infected PP population receiving PEG-IFN alfa-2a and PEG-IFN alfa-2b. EOT= 12, 24, 48 or 72 weeks after initiation of treatment. No participants were analysed for arm 'Genotype Unknown'.
Time frame: At 24 weeks after EOT
A total of 1656 participants were enrolled in this study conducted from January 2008 to August 2011 at 111 centres in United States.
| Milestone | Genotype 1 (G1) | Genotype 2 (G2) | Genotype 3 (G3) | Genotype 4 (G4) | Genotype 5/6 (G5/6) | Genotype Unknown (UNK) |
|---|---|---|---|---|---|---|
| Started | 1006 | 348 | 257 | 25 | 7 | 13 |
| Completed | 317 | 177 | 111 | 8 | 3 | 7 |
| Not completed | 689 | 171 | 146 | 17 | 4 | 6 |
| Withdrew: Adverse event | 18 | 1 | 6 | 0 | 0 | 0 |
| Withdrew: Death | 5 | 0 | 1 | 0 | 0 | 0 |
| Withdrew: Lack of efficacy | 22 | 1 | 2 | 1 | 0 | 0 |
| Withdrew: Physician decision | 6 | 2 | 3 | 0 | 0 | 0 |
| Withdrew: Protocol violation | 12 | 6 | 0 | 0 | 0 | 0 |
| Withdrew: Withdrawal by subject | 29 | 11 | 6 | 0 | 0 | 0 |
| Withdrew: Administrative | 6 | 4 | 2 | 0 | 0 | 0 |
| Withdrew: Not met inclusion/exclusion criteria | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Early termination | 2 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Failed to return | 298 | 107 | 68 | 7 | 2 | 3 |
| Withdrew: Lab test not done | 9 | 0 | 2 | 1 | 0 | 0 |
| Withdrew: Miscellaneous | 28 | 10 | 18 | 1 | 0 | 0 |
| Withdrew: Non responders | 123 | 2 | 7 | 2 | 0 | 1 |
| Withdrew: Not categorised | 9 | 2 | 6 | 1 | 0 | 0 |
| Withdrew: Relapse | 16 | 4 | 3 | 0 | 0 | 0 |
| Withdrew: Results not available | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Screen failure | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Spontaneous cure | 1 | 0 | 0 | 0 | 0 | 0 |
| Withdrew: Treatment never started | 85 | 19 | 19 | 3 | 2 | 2 |
| Withdrew: Treatment stopped | 12 | 1 | 2 | 1 | 0 | 0 |
| Withdrew: Other | 5 | 1 | 1 | 0 | 0 | 0 |
Sustained virological response (SVR) was defined as virological response (VR) at 24 weeks after end of treatment (EOT). Virological response was defined as hepatitis C virus ribonucleic acid (HCV RNA) of \<15 international units per milliliter (IU/mL) as assessed by COBAS AmpliPrep/COBAS TaqMan (CAP/CTM) or another HCV RNA test with at least the same degree of sensitivity. The CAP/CTM test is an in vitro nucleic acid amplification test for the quantification of HCV. This test possesses a high sensitivity (lower limit of detection \[LLOD\] 15 IU/mL) and a broad linear range of quantification (43 IU/mL up to 69 million IU/mL) in all HCV genotypes. The SVR is reported in treatment naive HCV mono-infected modified all-treated (mTRT) population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b. The EOT was 12, 24, 48 or 72 weeks after initiation of treatment.
| percentage of participants | Genotype 1 (G1) | Genotype 2 (G2) | Genotype 3 (G3) | Genotype 4 (G4) | Genotype 5/6 (G5/6) | Genotype Unknown (UNK) |
|---|---|---|---|---|---|---|
| Peg IFN Alfa 2a (n=568,221,159,16,2,1) | 30.3 (26.5 to 34.2) | 55.7 (48.8 to 62.3) | 43.4 (35.6 to 51.5) | 31.3 (11.0 to 58.7) | 100.0 (15.8 to 100.0) | 0.0 (0.0 to 97.5) |
| Peg IFN Alfa 2b (n=106,46,29,2,1,1) | 23.6 (15.9 to 32.8) | 50.0 (34.9 to 65.1) | 37.9 (20.7 to 57.7) | 50.0 (1.3 to 98.7) | 0.0 (0.0 to 97.5) | 0.0 (0.0 to 97.5) |
Sustained virological response was defined as VR at 24 weeks after EOT. Virological response was defined as HCV RNA of \<15 IU/mL as assessed by CAP/CTM or another HCV RNA test with at least the same degree of sensitivity. The CAP/CTM test is an in vitro nucleic acid amplification test for the quantification of HCV. This test possesses a high sensitivity (LLOD 15 IU/mL) and a broad linear range of quantification (43 IU/mL up to 69 million IU/mL) in all HCV genotypes. The SVR is reported in treatment naive HCV mono-infected per protocol (PP) population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b. The EOT was 12, 24, 48 or 72 weeks after initiation of treatment.
| percentage of participants | Genotype 1 (G1) | Genotype 2 (G2) | Genotype 3 (G3) | Genotype 4 (G4) | Genotype 5/6 (G5/6) | Genotype Unknown (UNK) |
|---|---|---|---|---|---|---|
| Peg IFN Alfa 2a (n=476,190,123,14,2,1) | 31.5 (27.4 to 35.9) | 57.4 (50.0 to 64.5) | 48.8 (39.7 to 58.0) | 35.7 (12.8 to 64.9) | 100.0 (15.8 to 100.0) | 0.0 (0.0 to 97.5) |
| Peg IFN Alfa 2b (n=88,41,28,2,1,1) | 26.1 (17.3 to 36.6) | 48.8 (32.9 to 64.9) | 35.7 (18.6 to 55.9) | 50.0 (1.3 to 98.7) | 0.0 (0.0 to 97.5) | 0.0 (0.0 to 97.5) |
Modified sustained virological response (mSVR) was defined as modified virological response (mVR) of HCV RNA \<50 IU/mL at 24 weeks after EOT. The mSVR is reported in treatment naive HCV mono-infected mTRT population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b. The EOT was 12, 24, 48 or 72 weeks after initiation of treatment.
| percentage of participants | Genotype 1 (G1) | Genotype 2 (G2) | Genotype 3 (G3) | Genotype 4 (G4) | Genotype 5/6 (G5/6) | Genotype Unknown (UNK) |
|---|---|---|---|---|---|---|
| Peg IFN Alfa 2a (n=568,221,159,16,2,1) | 30.6 (26.9 to 34.6) | 56.1 (49.3 to 62.8) | 43.4 (35.6 to 51.5) | 31.3 (11.0 to 58.7) | 100.0 (15.8 to 100.0) | 0.0 (0.0 to 97.5) |
| Peg IFN Alfa 2b (n=106,46,29, 2,1,1) | 23.6 (15.9 to 32.8) | 50.0 (34.9 to 65.1) | 37.9 (20.7 to 57.7) | 50.0 (1.3 to 98.7) | 0.0 (0.0 to 97.5) | 0.0 (0.0 to 97.5) |
Modified sustained virological response is defined as mVR of HCV RNA \<50 IU/mL at 24 weeks after EOT. The mSVR is reported in treatment naive HCV mono-infected PP population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b. The EOT was 12, 24, 48 or 72 weeks after initiation of treatment.
| percentage of participants | Genotype 1 (G1) | Genotype 2 (G2) | Genotype 3 (G3) | Genotype 4 (G4) | Genotype 5/6 (G5/6) | Genotype Unknown (UNK) |
|---|---|---|---|---|---|---|
| Peg IFN Alfa 2a (n=476,190,123,14,2,1) | 31.9 (27.8 to 36.3) | 57.9 (50.5 to 65.0) | 48.8 (39.7 to 58.0) | 35.7 (12.8 to 64.9) | 100.0 (15.8 to 100.0) | 0.0 (0.0 to 97.5) |
| Peg IFN Alfa 2b (n=88,41,28,2,1,1) | 26.1 (17.3 to 36.6) | 48.8 (32.9 to 64.9) | 35.7 (18.6 to 55.9) | 50.0 (1.3 to 98.7) | 0.0 (0.0 to 97.5) | 0.0 (0.0 to 97.5) |
The probability that a participant who developed VR by Week 4 and 12 and also achieved mSVR at 24 weeks after EOT was called the positive predictive value (PPV) of the VR by Wk 4 for mSVR. The probability that a participant who failed to develop VR by Wk 4 and 12 and also failed to achieve mSVR at 24 weeks after EOT was called the negative predictive value (NPV) of the VR by Wk 4 and 12 for mSVR. Predictive values of VR are reported in treatment naive HCV mono-infected mTRT participants who received PEG-IFN alfa-2a and PEG-IFN alfa-2b. The EOT was 12, 24, 48 or 72 weeks after initiation of treatment.
| percentage of participants | Genotype 1 (G1) | Genotype 2 (G2) | Genotype 3 (G3) | Genotype 4 (G4) | Genotype 5/6 (G5/6) | Genotype Unknown (UNK) |
|---|---|---|---|---|---|---|
| Wk4,PegIFNAlfa2a,PPV (n=568,221,159,16,2,1) | 53.8 (44.9 to 62.6) | 62.0 (54.5 to 69.0) | 56.1 (46.5 to 65.4) | 20.0 (0.5 to 71.6) | 100.0 (2.5 to 100.0) | 0.0 (0.0 to 97.5) |
| Wk4, PegIFNAlfa2a,NPV (n=568,221,159,16,2,1) | 76.7 (72.3 to 80.7) | 78.1 (60.0 to 90.7) | 88.1 (74.4 to 96.0) | 60.0 (26.2 to 87.8) | 0.0 (0.0 to 97.5) | NA (NA to NA) |
| Wk4, PegIFNAlfa2b, PPV (n=106,46,29,2,1,1) | 52.6 (28.9 to 75.6) | 52.6 (35.8 to 69.0) | 50.0 (27.2 to 72.8) | 50.0 (1.3 to 98.7) | 0.0 (0.0 to 97.5) | NA (NA to NA) |
| Wk4, PegIFNAlfa2b, NPV (n=106,46,29,2,1,1) | 81.6 (71.0 to 89.5) | 57.1 (18.4 to 90.1) | 87.5 (47.3 to 99.7) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Wk12,PegIFNAlfa2a,PPV (n=568,221,159,16,2,1) | 48.4 (42.7 to 54.1) | 59.0 (52.1 to 65.8) | 51.1 (42.3 to 59.9) | 50.0 (18.7 to 81.3) | 100.0 (15.8 to 100.0) | 0.0 (0.0 to 97.5) |
| Wk12,PegIFNAlfa2a, NPV(n=568,221,159,16,2,1) | 91.3 (87.1 to 94.5) | 100.0 (71.5 to 100.0) | 95.8 (78.9 to 99.9) | 100.0 (47.8 to 100.0) | NA (NA to NA) | NA (NA to NA) |
| Wk12,PegIFNAlfa2b, PPV (n=106,46,29,2,1,1) | 52.4 (36.4 to 68.0) | 50.0 (34.6 to 65.4) | 40.7 (22.4 to 61.2) | 50.0 (1.3 to 98.7) | 0.0 (0.0 to 97.5) | NA (NA to NA) |
| Wk12, PegIFNAlfa2b, NPV (n=106, 46,29, 2,1,1) | 96.6 (88.3 to 99.6) | 50.0 (1.3 to 98.7) | 100.0 (15.8 to 100.0) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
The probability that a participant who developed VR by Week 4 and 12 and also achieved mSVR at 24 weeks after EOT was called the PPV of the VR by Wk 4 for mSVR. The probability that a participant who failed to develop VR by Wk 4 and 12 and also failed to achieve mSVR at 24 weeks after EOT was called the NPV of the VR by Wk 4 and 12 for mSVR. Predictive values of VR are reported in treatment naive HCV mono-infected PP population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b. The EOT was 12, 24, 48 or 72 weeks after initiation of treatment.
| percentage of participants | Genotype 1 (G1) | Genotype 2 (G2) | Genotype 3 (G3) | Genotype 4 (G4) | Genotype 5/6 (G5/6) | Genotype Unknown (UNK) |
|---|---|---|---|---|---|---|
| Wk4,PegIFNAlfa2a,PPV (n=476,190,123,14,2,1) | 54.1 (44.3 to 63.7) | 62.4 (54.6 to 69.8) | 55.0 (44.7 to 65.0) | 20.0 (0.5 to 71.6) | 100.0 (2.5 to 100.0) | 0.0 (0.0 to 97.5) |
| Wk4, PegIFNAlfa2a,NPV (n=476,190,123,14,2,1) | 75.4 (70.5 to 79.8) | 70.8 (48.9 to 87.4) | 77.3 (54.6 to 92.2) | 50.0 (15.7 to 84.3) | 0.0 (0.0 to 97.5) | NA (NA to NA) |
| Wk4, PegIFNAlfa2b, PPV (n=88,41,28,2,1,1) | 50.0 (24.7 to 75.3) | 51.5 (33.5 to 69.2) | 47.4 (24.4 to 71.1) | 50.0 (1.3 to 98.7) | 0.0 (0.0 to 97.5) | NA (NA to NA) |
| Wk4, PegIFNAlfa2b, NPV (n=88,41,28,2,1,1) | 78.1 (66.0 to 87.5) | 57.1 (18.4 to 90.1) | 87.5 (47.3 to 99.7) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
| Wk12,PegIFNAlfa2a,PPV (n=476,190,123,14,2,1) | 49.6 (43.4 to 55.8) | 59.1 (51.7 to 66.3) | 51.3 (41.8 to 60.7) | 50.0 (18.7 to 81.3) | 100.0 (15.8 to 100.0) | 0.0 (0.0 to 97.5) |
| Wk12,PegIFNAlfa2a, NPV(n=476, 190,123,14,2,1) | 90.5 (85.7 to 94.1) | 100.0 (39.8 to 100.0) | 87.5 (47.3 to 99.7) | 100.0 (29.2 to 100.0) | NA (NA to NA) | NA (NA to NA) |
| Wk12,PegIFNAlfa2b, PPV (n=88,41,28,2,1,1) | 55.6 (38.1 to 72.1) | 48.7 (32.4 to 65.2) | 38.5 (20.2 to 59.4) | 50.0 (1.3 to 98.7) | 0.0 (0.0 to 97.5) | NA (NA to NA) |
| Wk12, PegIFNAlfa2b, NPV (n=88,41,28,2,1,1) | 95.8 (85.7 to 99.5) | 50.0 (1.3 to 98.7) | 100.0 (15.8 to 100.0) | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) |
Virological Response (VR) was defined as HCV RNA \<15 IU/mL as assessed by COBAS AmpliPrep/COBAS TaqMan (HCV) (CAP/CTM) or another HCV RNA test with at least the same degree of sensitivity. The CAP/CTM test is an in vitro nucleic acid amplification test for the quantification of HCV. This test possesses a high sensitivity (lower limit of detection 15 IU/mL) and a broad linear range of quantification (43 IU/mL up to 69 million IU/mL) in all HCV genotypes. PEOT= Post End of Treatment. EOT= 12, 24, 48 or 72 weeks after initiation of treatment.
| percentage of participants | Genotype 1 (G1) | Genotype 2 (G2) | Genotype 3 (G3) | Genotype 4 (G4) | Genotype 5/6 (G5/6) | Genotype Unknown (UNK) |
|---|---|---|---|---|---|---|
| Wk2,PegIFNAlfa2a (n=568,221,159 ,16,2,1) | 6.5 (4.6 to 8.9) | 25.8 (20.2 to 32.1) | 20.8 (14.7 to 27.9) | 12.5 (1.6 to 38.3) | 0.0 (0.0 to 84.2) | 100.0 (2.5 to 100.0) |
| Wk2,PegIFNAlfa2b (n=106,46,29,2,1,1) | 2.8 (0.6 to 8.0) | 17.4 (7.8 to 31.4) | 24.1 (10.3 to 43.5) | 0.0 (0.0 to 84.2) | 100.0 (2.5 to 100.0) | 0.0 (0.0 to 97.5) |
| Wk4,PegIFNAlfa2a (n=568,221,159,16,2,1) | 22.9 (19.5 to 26.6) | 83.3 (77.7 to 87.9) | 71.7 (64.0 to 78.5) | 31.3 (11.0 to 58.7) | 50.0 (1.3 to 98.7) | 100.0 (2.5 to 100.0) |
| Wk4,PegIFNAlfa2b (n=106,46,29,2,1,1) | 17.9 (11.2 to 26.6) | 82.6 (68.6 to 92.2) | 69.0 (49.2 to 84.7) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) | 0.0 (0.0 to 97.5) |
| Wk12,PegIFNAlfa2a (n=568,221,159,16,2,1) | 54.9 (50.7 to 59.1) | 95.0 (91.3 to 97.5) | 83.6 (77.0 to 89.0) | 62.5 (35.4 to 84.8) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) |
| Wk12,PegIFNAlfa2b (n=106,46,29,2,1,1) | 39.6 (30.3 to 49.6) | 95.7 (85.2 to 99.5) | 93.1 (77.2 to 99.2) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) | 0.0 (0.0 to 97.5) |
| EOT,PegIFNAlfa2a (n=568,221,159,16,2,1) | 55.3 (51.1 to 59.4) | 85.5 (80.2 to 89.9) | 74.2 (66.7 to 80.8) | 56.3 (29.9 to 80.2) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) |
| EOT,PegIFNAlfa2b (n=106,46,29,2,1,1) | 38.7 (29.4 to 48.6) | 84.8 (71.1 to 93.7) | 72.4 (52.8 to 87.3) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) | 0.0 (0.0 to 97.5) |
| 12Wk PEOT,PegIFNAlfa2a (n=568,221,159,16,2,1) | 34.5 (30.6 to 38.6) | 59.7 (52.9 to 66.3) | 48.4 (40.4 to 56.5) | 31.3 (11.0 to 58.7) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) |
| 12Wk PEOT,PegIFNAlfa2b (n=106,46,29,2,1,1) | 29.2 (20.8 to 38.9) | 54.3 (39.0 to 69.1) | 44.8 (26.4 to 64.3) | 100.0 (15.8 to 100.0) | 0.0 (0.0 to 97.5) | 0.0 (0.0 to 97.5) |
Virological response (VR) was defined as HCV RNA \<15 IU/mL as assessed by CAP/CTM or another HCV RNA test with at least the same degree of sensitivity. The CAP/CTM test is an in vitro nucleic acid amplification test for the quantification of HCV. This test possesses a high sensitivity (LLOD 15 IU/mL) and a broad linear range of quantification (43 IU/mL up to 69 million IU/mL) in all HCV genotypes. The VR is reported in treatment naive HCV mono-infected PP population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b. The EOT was 12, 24, 48 or 72 weeks after initiation of treatment. PEOT= Post End of Treatment
| percentage of participants | Genotype 1 (G1) | Genotype 2 (G2) | Genotype 3 (G3) | Genotype 4 (G4) | Genotype 5/6 (G5/6) | Genotype Unknown (UNK) |
|---|---|---|---|---|---|---|
| Wk2,PegIFNAlfa2a (n=476,190,123,14,2,1) | 7.4 (5.2 to 10.1) | 28.9 (22.6 to 36.0) | 23.6 (16.4 to 32.1) | 14.3 (1.8 to 42.8) | 0.0 (0.0 to 84.2) | 100.0 (2.5 to 100.0) |
| Wk2,PegIFNAlfa2b (n=88,41,28,2,1,1) | 3.4 (0.7 to 9.6) | 19.5 (8.8 to 34.9) | 25.0 (10.7 to 44.9) | 0.0 (0.0 to 84.2) | 100.0 (2.5 to 100.0) | 0.0 (0.0 to 97.5) |
| Wk4,PegIFNAlfa2a (n=476,190,123,14,2,1) | 22.9 (19.2 to 26.9) | 86.8 (81.2 to 91.3) | 81.3 (73.3 to 87.8) | 35.7 (12.8 to 64.9) | 50.0 (1.3 to 98.7) | 100.0 (2.5 to 100.0) |
| Wk4,PegIFNAlfa2b (n=88,41,28,2,1,1) | 18.2 (10.8 to 27.8) | 80.5 (65.1 to 91.2) | 67.9 (47.6 to 84.1) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) | 0.0 (0.0 to 97.5) |
| Wk12,PegIFNAlfa2a (n=476,190,123,14,2,1) | 55.5 (50.9 to 60.0) | 97.9 (94.7 to 99.4) | 93.5 (87.6 to 97.2) | 71.4 (41.9 to 91.6) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) |
| Wk12,PegIFNAlfa2b (n=88,41,28,2,1,1) | 40.9 (30.5 to 51.9) | 95.1 (83.5 to 99.4) | 92.9 (76.5 to 99.1) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) | 0.0 (0.0 to 97.5) |
| EOT,PegIFNAlfa2a (n=476,190,123,14,2,1) | 55.5 (50.9 to 60.0) | 88.9 (83.6 to 93.0) | 81.3 (73.3 to 87.8) | 64.3 (35.1 to 87.2) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) |
| EOT,PegIFNAlfa2b (n=88,41,28,2,1,1) | 43.2 (32.7 to 54.2) | 85.4 (70.8 to 94.4) | 71.4 (51.3 to 86.8) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) | 0.0 (0.0 to 97.5) |
| Wk12 PEOT,PegIFNAlfa2a (n=476,190,123,14,2,1) | 35.5 (31.2 to 40.0) | 62.1 (54.8 to 69.0) | 52.8 (43.6 to 61.9) | 35.7 (12.8 to 64.9) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) |
| Wk12 EOT,PegIFNAlfa2b (n=88,41,28,2,1,1) | 30.7 (21.3 to 41.4) | 51.2 (35.1 to 67.1) | 42.9 (24.5 to 62.8) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) | 0.0 (0.0 to 97.5) |
Modified virological response (mVR) was defined as HCV RNA \<50 IU/mL as assessed by CAP/CTM or another HCV RNA test with at least the same degree of sensitivity. The CAP/CTM test is an in vitro nucleic acid amplification test for the quantification of HCV. This test possesses a high sensitivity (LLOD 15 IU/mL) and a broad linear range of quantification (43 IU/mL up to 69 million IU/mL) in all HCV genotypes. The mVR is reported in treatment naive HCV mono-infected mTRT population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b. The EOT was 12, 24, 48 or 72 weeks after initiation of treatment. PEOT= Post End of Treatment
| percentage of participants | Genotype 1 (G1) | Genotype 2 (G2) | Genotype 3 (G3) | Genotype 4 (G4) | Genotype 5/6 (G5/6) | Genotype Unknown (UNK) |
|---|---|---|---|---|---|---|
| Wk2, Peg IFN Alfa 2a (n=568,221,159,16,2,1) | 7.6 (5.5 to 10.1) | 28.5 (22.7 to 34.9) | 25.8 (19.2 to 33.3) | 18.8 (4.0 to 45.6) | 50.0 (1.3 to 98.7) | 100.0 (2.5 to 100.0) |
| Wk2, Peg IFN Alfa 2b (n=106,46,29,2,1,1) | 3.8 (1.0 to 9.4) | 19.6 (9.4 to 33.9) | 31.0 (15.3 to 50.8) | 0.0 (0.0 to 84.2) | 100.0 (2.5 to 100.0) | 0.0 (0.0 to 97.5) |
| Wk4, Peg IFN Alfa 2a (n=568,221,159,16,2,1) | 25.9 (22.3 to 29.7) | 85.5 (80.2 to 89.9) | 75.5 (68.0 to 81.9) | 37.5 (15.2 to 64.6) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) |
| Wk4, Peg IFN Alfa 2b (n=106,46,29,2,1,1) | 22.6 (15.1 to 31.8) | 84.8 (71.1 to 93.7) | 75.9 (56.5 to 89.7) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) | 0.0 (0.0 to 97.5) |
| Wk12, Peg IFN Alfa 2a (n=568,221,159,16,2,1) | 58.1 (53.9 to 62.2) | 95.5 (91.8 to 97.8) | 85.5 (79.1 to 90.6) | 62.5 (35.4 to 84.8) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) |
| Wk12,Peg IFN Alfa 2b (n=106,46,29,2,1,1) | 43.4 (33.8 to 53.4) | 95.7 (85.2 to 99.5) | 93.1 (77.2 to 99.2) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) | 0.0 (0.0 to 97.5) |
| EOT, Peg IFN Alfa 2a (n=568,221,159,16,2,1) | 56.2 (52.0 to 60.3) | 86.9 (81.7 to 91.0) | 75.5 (68.0 to 81.9) | 56.3 (29.9 to 80.2) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) |
| EOT, Peg IFN Alfa 2b (n=106,46,29,2,1,1) | 40.6 (31.1 to 50.5) | 87.0 (73.7 to 95.1) | 72.4 (52.8 to 87.3) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) | 0.0 (0.0 to 97.5) |
| 12wk PEOT,PegIFNAlfa2a(n=568,221,159,16,2,1) | 34.9 (30.9 to 38.9) | 60.6 (53.9 to 67.1) | 48.4 (40.4 to 56.5) | 37.5 (15.2 to 64.6) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) |
| 12wk PEOT, PegIFNAlfa2b(n=106,46,29,2,1,1) | 29.2 (20.8 to 38.9) | 54.3 (39.0 to 69.1) | 44.8 (26.4 to 64.3) | 100.0 (15.8 to 100.0) | 0.0 (0.0 to 97.5) | 0.0 (0.0 to 97.5) |
Modified virological response (mVR) is defined as HCV RNA \<50 IU/mL as assessed by CAP/CTM or another HCV RNA test with at least the same degree of sensitivity. The CAP/CTM test is an in vitro nucleic acid amplification test for the quantification of HCV. This test possesses a high sensitivity (LLOD 15 IU/mL) and a broad linear range of quantification (43 IU/mL up to 69 million IU/mL) in all HCV genotypes. The mVR is reported in treatment naive HCV mono-infected PP population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b. The EOT was 12, 24, 48 or 72 weeks after initiation of treatment. PEOT= Post End of Treatment
| percentage of participants | Genotype 1 (G1) | Genotype 2 (G2) | Genotype 3 (G3) | Genotype 4 (G4) | Genotype 5/6 (G5/6) | Genotype Unknown (UNK) |
|---|---|---|---|---|---|---|
| Wk2, Peg IFN Alfa 2a (n=476,190,123,14,2,1) | 7.8 (5.5 to 10.6) | 32.1 (25.5 to 39.2) | 28.5 (20.7 to 37.3) | 21.4 (4.7 to 50.8) | 50.0 (1.3 to 98.7) | 100.0 (2.5 to 100.0) |
| Wk2, Peg IFN Alfa 2b (n=88,41,28,2,1,1) | 3.4 (0.7 to 9.6) | 19.5 (8.8 to 34.9) | 32.1 (15.9 to 52.4) | 0.0 (0.0 to 84.2) | 100.0 (2.5 to 100.0) | 0.0 (0.0 to 97.5) |
| Wk4, Peg IFN Alfa 2a (n=476,190,123,14,2,1) | 25.4 (21.6 to 29.6) | 89.5 (84.2 to 93.5) | 83.7 (76.0 to 89.8) | 42.9 (17.7 to 71.1) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) |
| Wk4, Peg IFN Alfa 2b (n=88,41,28,2,1,1) | 23.9 (15.4 to 34.1) | 82.9 (67.9 to 92.8) | 75.0 (55.1 to 89.3) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) | 0.0 (0.0 to 97.5) |
| Wk12, Peg IFN Alfa 2a (n=476,190,123,14,2,1) | 58.8 (54.3 to 63.3) | 98.4 (95.5 to 99.7) | 94.3 (88.6 to 97.7) | 71.4 (41.9 to 91.6) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) |
| Wk12,Peg IFN Alfa 2b (n=88,41,28,2,1,1) | 45.5 (34.8 to 56.4) | 95.1 (83.5 to 99.4) | 92.9 (76.5 to 99.1) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) | 0.0 (0.0 to 97.5) |
| EOT, Peg IFN Alfa 2a (n=476,190,123,14,2,1) | 56.5 (51.9 to 61.0) | 90.0 (84.8 to 93.9) | 81.3 (73.3 to 87.8) | 64.3 (35.1 to 87.2) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) |
| EOT, Peg IFN Alfa 2b (n=88,41,28,2,1,1) | 44.3 (33.7 to 55.3) | 85.4 (70.8 to 94.4) | 71.4 (51.3 to 86.8) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) | 0.0 (0.0 to 97.5) |
| 12wk PEOT,PegIFNAlfa2a(n=476,190,123,14,2,1) | 35.9 (31.6 to 40.4) | 63.2 (55.9 to 70.0) | 52.8 (43.6 to 61.9) | 42.9 (17.7 to 71.1) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) |
| 12wk PEOT, PegIFNAlfa2b(n=88,41,28,2,1,1) | 30.7 (21.3 to 41.4) | 51.2 (35.1 to 67.1) | 42.9 (24.5 to 62.8) | 100.0 (15.8 to 100.0) | 0.0 (0.0 to 97.5) | 0.0 (0.0 to 97.5) |
Participants with 2-logarithm (log) drop in HCV RNA including HCV RNA values \<50 IU/mL in the serum from baseline to Week 2, Week 4 and Week 12, expressed in terms of a logarithmic scale with base 10 were evaluated and reported. A 2 log drop in HCV RNA was defined as drop of HCV viral load by 99%. The 2 log drop in HCV RNA is reported in treatment naive HCV mono-infected mTRT population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b.
| percentage of participants | Genotype 1 (G1) | Genotype 2 (G2) | Genotype 3 (G3) | Genotype 4 (G4) | Genotype 5/6 (G5/6) | Genotype Unknown (UNK) |
|---|---|---|---|---|---|---|
| Wk2, Peg IFN Alfa 2a (n=568,221,159,16,2,1) | 19.9 (16.7 to 23.4) | 53.8 (47.0 to 60.6) | 48.4 (40.4 to 56.5) | 25.0 (7.3 to 52.4) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) |
| Wk2, Peg IFN Alfa 2b (n=106,46,29,2,1,1) | 17.0 (10.4 to 25.5) | 43.5 (28.9 to 58.9) | 62.1 (42.3 to 79.3) | 50.0 (1.3 to 98.7) | 100.0 (2.5 to 100.0) | 0.0 (0.0 to 97.5) |
| Wk4, Peg IFN Alfa 2a (n=568,221,159,16,2,1) | 53.7 (49.5 to 57.9) | 95.9 (92.4 to 98.1) | 92.5 (87.2 to 96.0) | 50.0 (24.7 to 75.3) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) |
| Wk4, Peg IFN Alfa 2b (n=106,46,29,2,1,1) | 43.4 (33.8 to 53.4) | 95.7 (85.2 to 99.5) | 86.2 (68.3 to 96.1) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) | 0.0 (0.0 to 97.5) |
| Wk12, Peg IFN Alfa 2a (n=568,221,159,16,2,1) | 78.3 (74.7 to 81.7) | 99.5 (97.5 to 100.0) | 94.3 (89.5 to 97.4) | 62.5 (35.4 to 84.8) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) |
| Wk12,Peg IFN Alfa 2b (n=106,46,29,2,1,1) | 67.9 (58.2 to 76.7) | 97.8 (88.5 to 99.9) | 96.6 (82.2 to 99.9) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) | 0.0 (0.0 to 97.5) |
Participants with 2-log drop in HCV RNA including HCV RNA values \<50 IU/mL in the serum from baseline to Week 2, Week 4 and Week 12, expressed in terms of a logarithmic scale with base 10 were evaluated and reported. A 2 log drop in HCV RNA was defined as drop of HCV viral load by 99%. The 2 log drop in HCV RNA is reported in treatment naive HCV mono-infected PP population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b.
| percentage of participants | Genotype 1 (G1) | Genotype 2 (G2) | Genotype 3 (G3) | Genotype 4 (G4) | Genotype 5/6 (G5/6) | Genotype Unknown (UNK) |
|---|---|---|---|---|---|---|
| Wk2, Peg IFN Alfa 2a (n=476,190,123,14,2,1) | 21.0 (17.4 to 24.9) | 57.4 (50.0 to 64.5) | 52.0 (42.8 to 61.1) | 28.6 (8.4 to 58.1) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) |
| Wk2, Peg IFN Alfa 2b (n=88,41,28,2,1,1) | 19.3 (11.7 to 29.1) | 46.3 (30.7 to 62.6) | 64.3 (44.1 to 81.4) | 50.0 (1.3 to 98.7) | 100.0 (2.5 to 100.0) | 0.0 (0.0 to 97.5) |
| Wk4, Peg IFN Alfa 2a (n=476,190,123,14,2,1) | 54.6 (50.0 to 59.2) | 98.4 (95.5 to 99.7) | 96.7 (91.9 to 99.1) | 57.1 (28.9 to 82.3) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) |
| Wk4, Peg IFN Alfa 2b (n=88,41,28,2,1,1) | 47.7 (37.0 to 58.6) | 95.1 (83.5 to 99.4) | 85.7 (67.3 to 96.0) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) | 0.0 (0.0 to 97.5) |
| Wk12, Peg IFN Alfa 2a (n=476,190,123,14,2,1) | 79.6 (75.7 to 83.2) | 100.0 (98.1 to 100.0) | 98.4 (94.2 to 99.8) | 71.4 (41.9 to 91.6) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) |
| Wk12,Peg IFN Alfa 2b (n=88,41,28,2,1,1) | 72.7 (62.2 to 81.7) | 97.6 (87.1 to 99.9) | 96.4 (81.7 to 99.9) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) | 0.0 (0.0 to 97.5) |
Participants with 1-log drop in HCV RNA including HCV RNA values \<50 IU/mL in the serum from baseline to Week 2, Week 4 and Week 12, expressed in terms of a logarithmic scale with base 10 were evaluated and reported. A 1- log drop in HCV RNA was defined as drop of HCV viral load by 90%. The 1- log drop in HCV RNA was reported in treatment naive HCV mono-infected mTRT population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b.
| percentage of participants | Genotype 1 (G1) | Genotype 2 (G2) | Genotype 3 (G3) | Genotype 4 (G4) | Genotype 5/6 (G5/6) | Genotype Unknown (UNK) |
|---|---|---|---|---|---|---|
| Wk2, Peg IFN Alfa 2a (n=568,221,159,16,2,1) | 29.2 (25.5 to 33.2) | 56.1 (49.3 to 62.8) | 50.9 (42.9 to 58.9) | 31.3 (11.0 to 58.7) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) |
| Wk2, Peg IFN Alfa 2b (n=106,46,29,2,1,1) | 26.4 (18.3 to 35.9) | 45.7 (30.9 to 61.0) | 62.1 (42.3 to 79.3) | 50.0 (1.3 to 98.7) | 100.0 (2.5 to 100.0) | 0.0 (0.0 to 97.5) |
| Wk4, Peg IFN Alfa 2a (n=568,221,159,16,2,1) | 73.4 (69.6 to 77.0) | 97.3 (94.2 to 99.0) | 95.0 (90.3 to 97.8) | 68.8 (41.3 to 89.0) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) |
| Wk4, Peg IFN Alfa 2b (n=106,46,29,2,1,1) | 62.3 (52.3 to 71.5) | 95.7 (85.2 to 99.5) | 89.7 (72.6 to 97.8) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) | 0.0 (0.0 to 97.5) |
Participants with 1-log drop in HCV RNA including HCV RNA values \<50 IU/mL in the serum from baseline to Week 2, Week 4 and Week 12, expressed in terms of a logarithmic scale with base 10 were evaluated and reported. A 1- log drop in HCV RNA was defined as drop of HCV viral load by 90%. The 1- log drop in HCV RNA was reported in treatment naive HCV mono-infected PP population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b.
| percentage of participants | Genotype 1 (G1) | Genotype 2 (G2) | Genotype 3 (G3) | Genotype 4 (G4) | Genotype 5/6 (G5/6) | Genotype Unknown (UNK) |
|---|---|---|---|---|---|---|
| Wk2, Peg IFN Alfa 2a (n=476,190,123,14,2,1) | 31.1 (27.0 to 35.5) | 59.5 (52.1 to 66.5) | 53.7 (44.4 to 62.7) | 35.7 (12.8 to 64.9) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) |
| Wk2, Peg IFN Alfa 2b (n=88,41,28,2,1,1) | 29.5 (20.3 to 40.2) | 48.8 (32.9 to 64.9) | 64.3 (44.1 to 81.4) | 50.0 (1.3 to 98.7) | 100.0 (2.5 to 100.0) | 0.0 (0.0 to 97.5) |
| Wk4, Peg IFN Alfa 2a (n=476,190,123,14,2,1) | 74.6 (70.4 to 78.4) | 99.5 (97.1 to 100.0) | 98.4 (94.2 to 99.8) | 78.6 (49.2 to 95.3) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) |
| Wk4, Peg IFN Alfa 2b (n=88,41,28,2,1,1) | 65.9 (55.0 to 75.7) | 95.1 (83.5 to 99.4) | 89.3 (71.8 to 97.7) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) | 0.0 (0.0 to 97.5) |
| Wk12, Peg IFN Alfa 2a (n=476,190,123,14,2,1) | 91.6 (88.7 to 93.9) | 100.0 (98.1 to 100.0) | 99.2 (95.6 to 100.0) | 85.7 (57.2 to 98.2) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) |
| Wk12,Peg IFN Alfa 2b (n=88,41,28,2,1,1) | 83.0 (73.4 to 90.1) | 97.6 (87.1 to 99.9) | 96.4 (81.7 to 99.9) | 100.0 (15.8 to 100.0) | 100.0 (2.5 to 100.0) | 0.0 (0.0 to 97.5) |
The probability that a participant who developed VR by Wk 2 achieved mSVR at 24 weeks after EOT was called the PPV of the VR by Wk 4 for mSVR. The probability that a participant who failed to develop VR by Wk 4 and 12 and also failed to achieve mSVR at 24 weeks after EOT was called the NPV of the VR by Wk 4 and 12 for mSVR. Predictive Values of VR was reported in treatment naive HCV mono-infected mTRT population participants who received PEG-IFN alfa-2a and PEG-IFN alfa-2b. The EOT was 12, 24, 48 or 72 weeks after initiation of treatment.
| percentage of participants | Genotype 1 (G1) | Genotype 2 (G2) | Genotype 3 (G3) | Genotype 4 (G4) | Genotype 5/6 (G5/6) | Genotype Unknown (UNK) |
|---|---|---|---|---|---|---|
| Wk2, Peg IFNAlfa2a,PPV (n=568,221,159,16,2,1) | 45.9 (29.5 to 63.1) | 63.2 (49.3 to 75.6) | 54.5 (36.4 to 71.9) | 0.0 (0.0 to 84.2) | NA (NA to NA) | 0.0 (0.0 to 97.5) |
| Wk2,Peg IFNAlfa2a,NPV (n=568,221,159,16,2,1) | 69.5 (63.5 to 75.1) | 43.1 (31.4 to 55.3) | 64.9 (51.1 to 77.1) | 66.7 (29.9 to 92.5) | 0.0 (0.0 to 84.2) | NA (NA to NA) |
| Wk2, Peg IFNAlfa 2b, PPV (n=106,46,29,2,1,1) | 100.0 (29.2 to 100.0) | 62.5 (24.5 to 91.5) | 57.1 (18.4 to 90.1) | NA (NA to NA) | 0.0 (0.0 to 97.5) | NA (NA to NA) |
| Wk2, Peg IFNAlfa 2b, NPV (n=106,46,29,2,1,1) | 78.8 (65.3 to 88.9) | 50.0 (23.0 to 77.0) | 58.3 (27.7 to 84.8) | 100.0 (2.5 to 100.0) | NA (NA to NA) | NA (NA to NA) |
The probability that a participant who developed VR by Wk 2 and achieved mSVR at 24 weeks after EOT was called the PPV of the VR by Wk 4 for mSVR. The probability that a participant who failed to develop VR by Wk 2 and also failed to achieve mSVR at 24 weeks after EOT was called the NPV of the VR by Wk 2 for mSVR. Predictive values of VR is reported in treatment naive HCV mono-infected PP population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b. The EOT was 12, 24, 48 or 72 weeks after initiation of treatment.
| percentage of participants | Genotype 1 (G1) | Genotype 2 (G2) | Genotype 3 (G3) | Genotype 4 (G4) | Genotype 5/6 (G5/6) | Genotype Unknown (UNK) |
|---|---|---|---|---|---|---|
| Wk2, Peg IFNAlfa2a, PPV (n=476,190,123,14,2,1) | 48.6 (31.4 to 66.0) | 61.8 (47.7 to 74.6) | 51.7 (32.5 to 70.6) | 0.0 (0.0 to 84.2) | NA (NA to NA) | 0.0 (0.0 to 97.5) |
| Wk2, PegIFNAlfa2a, NPV(n=476,190,123,14,2,1) | 67.0 (60.3 to 73.2) | 33.3 (21.7 to 46.7) | 56.1 (39.7 to 71.5) | 57.1 (18.4 to 90.1) | 0.0 (0.0 to 84.2) | NA (NA to NA) |
| Wk2, PegIFNAlfa2b, PPV(n=88,41,28,2,1,1) | 100.0 (29.2 to 100.0) | 62.5 (24.5 to 91.5) | 57.1 (18.4 to 90.1) | NA (NA to NA) | 0.0 (0.0 to 97.5) | NA (NA to NA) |
| Wk2, PegIFNAlfa2b, NPV(n=88,41,28,2,1,1) | 77.3 (62.2 to 88.5) | 53.8 (25.1 to 80.8) | 58.3 (27.7 to 84.8) | 100.0 (2.5 to 100.0) | NA (NA to NA) | NA (NA to NA) |
Rapid virological response (RVR) was defined as VR by Wk 4, Modified rapid virological response (mRVR) was defined as mVR by Wk 4, complete early virological response (cEVR) was defined as VR by Wk 12, but no RVR, modified complete early virological response (mcEVR) was defined as mVR by Wk 12, but no mRVR, partial early virological response (pEVR) was defined as at least a 2-log10 drop in HCV RNA as compared to baseline (including HCV RNA values \<50 IU/mL) by Wk 12, but no RVR and no cEVR, modified partial early virological response (mpEVR) was defined as at least a 2-log10 drop in HCV RNA as compared to baseline by Wk 12, but no mRVR and no mcEVR. The data is reported in treatment naive HCV mono-infected mTRT participants who received PEG-IFN alfa-2a and PEG-IFN alfa-2b.
| participants | Genotype 1 (G1) | Genotype 2 (G2) | Genotype 3 (G3) | Genotype 4 (G4) | Genotype 5/6 (G5/6) | Genotype Unknown (UNK) |
|---|---|---|---|---|---|---|
| Peg IFN Alfa 2a RVR(n= 568,221,159,16,2,1) | 130 | 184 | 114 | 5 | 1 | 1 |
| Peg IFN Alfa 2b RVR (n= 106,46,29,2,1,1) | 19 | 38 | 20 | 2 | 1 | 0 |
| Peg IFN Alfa 2a mRVR(n= 568,221,159,16,2,1) | 147 | 189 | 120 | 6 | 2 | 1 |
| Peg IFN Alfa 2b mRVR(n= 106,46,29,2,1,1) | 24 | 39 | 22 | 2 | 1 | 0 |
RVR was defined as as VR by Wk 4, mRVR was defined as mVR by Wk 4, cEVR was defined as VR by Wk 12, but no RVR, mcEVR was defined as mVR by Wk 12, but no mRVR, pEVR was defined as at least a 2-log10 drop in HCV RNA as compared to baseline (including HCV RNA values \<50 IU/mL) by Wk 12, but no RVR and no cEVR, mpEVR was defined as at least a 2-log10 drop in HCV RNA as compared to baseline by Wk 12, but no mRVR and no mcEVR. The data is reported in treatment naive HCV mono-infected PP population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b.
| participants | Genotype 1 (G1) | Genotype 2 (G2) | Genotype 3 (G3) | Genotype 4 (G4) | Genotype 5/6 (G5/6) | Genotype Unknown (UNK) |
|---|---|---|---|---|---|---|
| RVR, Peg IFN Alfa 2a (n=476,190,123,14,2,1) | 109 | 165 | 100 | 5 | 1 | 1 |
| RVR, Peg IFN Alfa 2b(n=88,41,28,2,1,1) | 16 | 33 | 19 | 2 | 1 | 0 |
| mRVR,Peg IFN Alfa 2a(n=476,190,123,14,2,1) | 121 | 170 | 103 | 6 | 2 | 1 |
| mRVR, Peg IFN Alfa 2b(n=88,41,28,2,1,1) | 21 | 34 | 21 | 2 | 1 | 0 |
| cEVR, Peg IFN Alfa 2a(n=476,190,123,14,2,1) | 155 | 21 | 15 | 5 | 1 | 0 |
Participants whose last test result in their respective follow-up time window showed mVR were considered to have maintained their modified end of treatment response (mEOT-R). Participants whose last test result in the respective follow-up time window did not show mVR, or who did not have a test result in the respective follow-up time window but whose last follow-up test result before the time window did not show mVR, were considered to have relapsed. Only participants with mEOT-R who had a HCV RNA measurement in the follow-up time window (without use of backward imputation), or whose last HCV RNA measurement at a follow-up time point before the time window did not show mVR, were included in the calculations. The number of participants with relapse was reported in treatment naive mTRT population who received PEG-IFN alfa-2a and PEG-IFN alfa-2b. The EOT was 12, 24, 48 or 72 weeks after initiation of treatment.
| Percentage of Participants | Genotype 1 (G1) | Genotype 2 (G2) | Genotype 3 (G3) | Genotype 4 (G4) | Genotype 5/6 (G5/6) | Genotype Unknown (UNK) |
|---|---|---|---|---|---|---|
| 12wk PEOT,PegIFN Alfa2a (n=153,94,63,4,1,1) | 24.8 | 8.5 | 22.2 | 0.0 | 0.0 | 0.0 |
| 12wk PEOT, PegIFN Alfa2b(n=19,18,9,2,0,0) | 10.5 | 11.1 | 0.0 | 0.0 | NA | NA |
Participants whose last test result in the follow-up time window showed mVR were considered to have maintained their modified end of treatment response (mEOT-R). Participants whose last test result in the respective follow-up time window did not show mVR, or who did not have a test result in the respective follow-up time window but whose last follow-up test result before the time window did not show mVR, were considered to have relapsed. Only participants with mEOT-R who had a HCV RNA measurement in the follow-up time window (without use of backward imputation), or whose last HCV RNA measurement at a follow-up time point before the time window did not show mVR, were included in the calculations. It was reported in treatment naive HCV mono-infected mTRT population receiving PEG-IFN alfa-2a and PEG-IFN alfa-2b. EOT= 12, 24, 48 or 72 weeks after initiation of treatment. No participants were analysed for arm 'Genotype Unknown'.
| Percentage of Participants | Genotype 1 (G1) | Genotype 2 (G2) | Genotype 3 (G3) | Genotype 4 (G4) | Genotype 5/6 (G5/6) | Genotype Unknown (UNK) |
|---|---|---|---|---|---|---|
| 24wk PEOT,PegIFN Alfa2a (n=236,136,84, 6, 2, 0) | 26.3 | 8.8 | 19.0 | 16.7 | 0.0 | — |
| 24wk PEOT, PegIFN Alfa2b(n=28, 25, 11, 1, 1, 0) | 10.7 | 8.0 | 0.0 | 0.0 | 100.0 | — |
Participants whose last test result in the follow-up time window showed mVR were considered to have maintained their modified end of treatment response (mEOT-R). Participants whose last test result in the respective follow-up time window did not show mVR, or who did not have a test result in the respective follow-up time window but whose last follow-up test result before the time window did not show mVR, were considered to have relapsed. Only participants with mEOT-R who had a HCV RNA measurement in the follow-up time window (without use of backward imputation), or whose last HCV RNA measurement at a follow-up time point before the time window did not show mVR, were included in the calculations. It was reported in treatment naive HCV mono-infected PP population receiving PEG-IFN alfa-2a and PEG-IFN alfa-2b. EOT= 12, 24, 48 or 72 weeks after initiation of treatment.
| Percentage of Participants | Genotype 1 (G1) | Genotype 2 (G2) | Genotype 3 (G3) | Genotype 4 (G4) | Genotype 5/6 (G5/6) | Genotype Unknown (UNK) |
|---|---|---|---|---|---|---|
| 12wk PEOT,PegINFAlfa2a (n=128,86,55,4,1,1) | 23.4 | 8.1 | 21.8 | 0.0 | 0.0 | 0.0 |
| 12wk PEOT, PegIFNAlfa2b(n=16,15,8,2,0,0) | 12.5 | 13.3 | 0.0 | 0.0 | NA | NA |
Participants whose last test result in the follow-up time window showed mVR were considered to have maintained their modified end of treatment response (mEOT-R). Participants whose last test result in the respective follow-up time window did not show mVR, or who did not have a test result in the respective follow-up time window but whose last follow-up test result before the time window did not show mVR, were considered to have relapsed. Only participants with mEOT-R who had a HCV RNA measurement in the follow-up time window (without use of backward imputation), or whose last HCV RNA measurement at a follow-up time point before the time window did not show mVR, were included in the calculations. It was reported in treatment naive HCV mono-infected PP population receiving PEG-IFN alfa-2a and PEG-IFN alfa-2b. EOT= 12, 24, 48 or 72 weeks after initiation of treatment. No participants were analysed for arm 'Genotype Unknown'.
| Percentage of Participants | Genotype 1 (G1) | Genotype 2 (G2) | Genotype 3 (G3) | Genotype 4 (G4) | Genotype 5/6 (G5/6) | Genotype Unknown (UNK) |
|---|---|---|---|---|---|---|
| 24wk PEOT,PegIFNAlfa2a (n=201, 120, 72, 6, 2, 0) | 24.4 | 8.3 | 18.1 | 16.7 | 0.0 | — |
| 24wk PEOT, PegIFNAlfa2b(n=26,22,10,1,1, 0) | 11.5 | 9.1 | 0.0 | 0.0 | 100.0 | — |
Collected over Up to 3 years and 8 months. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Total (PEG-IFN Alfa-2a +PEG-IFN Alfa-2b) | — | 130/1,441 (9%) | 841/1,441 (58.4%) |
| Event | Total (PEG-IFN Alfa-2a +PEG-IFN Alfa-2b) |
|---|---|
| PneumoniaInfections and infestations | 10/1441 |
| AnaemiaBlood and lymphatic system disorders | 10/1441 |
| DepressionPsychiatric disorders | 5/1441 |
| PancytopeniaBlood and lymphatic system disorders | 5/1441 |
| Chest painGeneral disorders | 5/1441 |
| SyncopeNervous system disorders | 4/1441 |
| CellulitisInfections and infestations | 3/1441 |
| AlcoholismPsychiatric disorders | 3/1441 |
| Psychotic disorderPsychiatric disorders | 3/1441 |
| Suicidal ideationPsychiatric disorders | 3/1441 |
| Event | Total (PEG-IFN Alfa-2a +PEG-IFN Alfa-2b) |
|---|---|
| AnaemiaBlood and lymphatic system disorders | 333/1441 |
| DepressionPsychiatric disorders | 234/1441 |
| InsomniaPsychiatric disorders | 224/1441 |
| FatigueGeneral disorders | 206/1441 |
| NauseaGastrointestinal disorders | 168/1441 |
| RashSkin and subcutaneous tissue disorders | 138/1441 |
| HeadacheNervous system disorders | 136/1441 |
| NeutropeniaBlood and lymphatic system disorders | 108/1441 |
| Influenza like illnessGeneral disorders | 104/1441 |
| AnxietyPsychiatric disorders | 92/1441 |
The All Patient Enrolled Population included every participant of whom there was any data in the PROPHESYS database.
| Age, Continuous(years) | Genotype 1 (G1) | Genotype 2 (G2) | Genotype 3 (G3) | Genotype 4 (G4) | Genotype 5/6 (G5/6) | Genotype Unknown (UNK) | Total |
|---|---|---|---|---|---|---|---|
| Mean | 48.4 ± 9.68 | 49.7 ± 9.74 | 46.9 ± 9.41 | 46.4 ± 10.59 | 53.3 ± 10.48 | 45.6 ± 10.72 | 48.4 ± 9.71 |
| Sex: Female, Male(Participants) | Genotype 1 (G1) | Genotype 2 (G2) | Genotype 3 (G3) | Genotype 4 (G4) | Genotype 5/6 (G5/6) | Genotype Unknown (UNK) | Total |
|---|---|---|---|---|---|---|---|
| Female | 419 | 148 | 110 | 5 | 3 | 7 | 692 |
| Male | 587 | 200 | 147 | 20 | 4 | 6 | 964 |
Showing the first 100 of 106 sites across 2 countries.
This study is completed, as verified in Jun 2016. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Hoffmann-La Roche